177 related articles for article (PubMed ID: 20151210)
1. Efficacy of a novel sphingosine kinase inhibitor in experimental Crohn's disease.
Maines LW; Fitzpatrick LR; Green CL; Zhuang Y; Smith CD
Inflammopharmacology; 2010 Apr; 18(2):73-85. PubMed ID: 20151210
[TBL] [Abstract][Full Text] [Related]
2. Attenuation of arthritis in rodents by a novel orally-available inhibitor of sphingosine kinase.
Fitzpatrick LR; Green C; Frauenhoffer EE; French KJ; Zhuang Y; Maines LW; Upson JJ; Paul E; Donahue H; Mosher TJ; Smith CD
Inflammopharmacology; 2011 Apr; 19(2):75-87. PubMed ID: 20936538
[TBL] [Abstract][Full Text] [Related]
3. Suppression of colitis-driven colon cancer in mice by a novel small molecule inhibitor of sphingosine kinase.
Chumanevich AA; Poudyal D; Cui X; Davis T; Wood PA; Smith CD; Hofseth LJ
Carcinogenesis; 2010 Oct; 31(10):1787-93. PubMed ID: 20688834
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of sphingosine kinase-2 suppresses inflammation and attenuates graft injury after liver transplantation in rats.
Liu Q; Rehman H; Shi Y; Krishnasamy Y; Lemasters JJ; Smith CD; Zhong Z
PLoS One; 2012; 7(7):e41834. PubMed ID: 22848628
[TBL] [Abstract][Full Text] [Related]
5. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2.
French KJ; Zhuang Y; Maines LW; Gao P; Wang W; Beljanski V; Upson JJ; Green CL; Keller SN; Smith CD
J Pharmacol Exp Ther; 2010 Apr; 333(1):129-39. PubMed ID: 20061445
[TBL] [Abstract][Full Text] [Related]
6. Recombinant expressed vasoactive intestinal peptide analogue ameliorates TNBS-induced colitis in rats.
Xu CL; Guo Y; Qiao L; Ma L; Cheng YY
World J Gastroenterol; 2018 Feb; 24(6):706-715. PubMed ID: 29456409
[TBL] [Abstract][Full Text] [Related]
7. Recombinant adeno-associated virus carrying thymosin β
Zheng XY; Lv YF; Li S; Li Q; Zhang QN; Zhang XT; Hao ZM
World J Gastroenterol; 2017 Jan; 23(2):242-255. PubMed ID: 28127198
[TBL] [Abstract][Full Text] [Related]
8. Experimental osteoarthritis in rats is attenuated by ABC294640, a selective inhibitor of sphingosine kinase-2.
Fitzpatrick LR; Green C; Maines LW; Smith CD
Pharmacology; 2011; 87(3-4):135-43. PubMed ID: 21346391
[TBL] [Abstract][Full Text] [Related]
9. Targeting ovarian cancer and chemoresistance through selective inhibition of sphingosine kinase-2 with ABC294640.
White MD; Chan L; Antoon JW; Beckman BS
Anticancer Res; 2013 Sep; 33(9):3573-9. PubMed ID: 24023282
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic effects of rectal administration of muscovite on experimental colitis in rats.
Chen Y; Chen Y; Liu WL; Zhou TH; Cai JT; Du Q; Wang LJ; Wu JG; Si JM
J Gastroenterol Hepatol; 2009 May; 24(5):912-9. PubMed ID: 19220658
[TBL] [Abstract][Full Text] [Related]
11. Use of artificial cell microcapsule containing thalidomide for treating TNBS-induced Crohn's disease in mice.
Fakhoury M; Coussa-Charley M; Al-Salami H; Kahouli I; Prakash S
Curr Drug Deliv; 2014; 11(1):146-53. PubMed ID: 24533726
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic evaluation of sulfasalazine, FTY720, and anti-IL-12/23p40 in a TNBS-induced Crohn's disease model.
Radi ZA; Heuvelman DM; Masferrer JL; Benson EL
Dig Dis Sci; 2011 Aug; 56(8):2283-91. PubMed ID: 21374065
[TBL] [Abstract][Full Text] [Related]
13. Orally administered emu oil attenuates disease in a mouse model of Crohn's-like colitis.
Mitchell CJ; Howarth GS; Chartier LC; Trinder D; Lawrance IC; Huang LS; Mashtoub S
Exp Biol Med (Maywood); 2020 Dec; 245(18):1697-1707. PubMed ID: 32903038
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of sphingosine kinase-2 in a murine model of lupus nephritis.
Snider AJ; Ruiz P; Obeid LM; Oates JC
PLoS One; 2013; 8(1):e53521. PubMed ID: 23301082
[TBL] [Abstract][Full Text] [Related]
15. Interleukin 16 is up-regulated in Crohn's disease and participates in TNBS colitis in mice.
Keates AC; Castagliuolo I; Cruickshank WW; Qiu B; Arseneau KO; Brazer W; Kelly CP
Gastroenterology; 2000 Oct; 119(4):972-82. PubMed ID: 11040184
[TBL] [Abstract][Full Text] [Related]
16. Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2.
Antoon JW; White MD; Slaughter EM; Driver JL; Khalili HS; Elliott S; Smith CD; Burow ME; Beckman BS
Cancer Biol Ther; 2011 Apr; 11(7):678-89. PubMed ID: 21307639
[TBL] [Abstract][Full Text] [Related]
17. ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancer.
Yang J; Yang C; Zhang S; Mei Z; Shi M; Sun S; Shi L; Wang Z; Wang Y; Li Z; Xie C
Cancer Biol Ther; 2015; 16(8):1194-204. PubMed ID: 26054751
[TBL] [Abstract][Full Text] [Related]
18. Targeting sphingosine kinase 2 by ABC294640 inhibits human skin squamous cell carcinoma cell growth.
Zhou J; Chen J; Yu H
Biochem Biophys Res Commun; 2018 Mar; 497(2):535-542. PubMed ID: 29428730
[TBL] [Abstract][Full Text] [Related]
19. The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo.
Venant H; Rahmaniyan M; Jones EE; Lu P; Lilly MB; Garrett-Mayer E; Drake RR; Kraveka JM; Smith CD; Voelkel-Johnson C
Mol Cancer Ther; 2015 Dec; 14(12):2744-52. PubMed ID: 26494858
[TBL] [Abstract][Full Text] [Related]
20. Sphingosine kinase inhibition exerts both pro- and anti-atherogenic effects in low-density lipoprotein receptor-deficient (LDL-R(-/-)) mice.
Poti F; Bot M; Costa S; Bergonzini V; Maines L; Varga G; Freise H; Robenek H; Simoni M; Nofer JR
Thromb Haemost; 2012 Mar; 107(3):552-61. PubMed ID: 22234485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
